ENVB Stock Analysis: Buy, Sell, or Hold?
ENVB - Enveric Biosciences, Inc. Common Stock
$1.53
-0.13 (-7.83%)
▼
5d:
-15.0%
30d:
-37.3%
90d:
-19.47%
HOLD
MODERATE Confidence
Analysis Updated: Jun 12, 2026 12:00 AM ET
Earnings: May 13, 2026
0d
Get Alerted When ENVB Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: ENVB shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: ENVB shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: ENVB is currently trading at $1.53, which is considered oversold relative to its 30-day fair value range of $1.79 to $2.81.
Technical Outlook: Technically, ENVB is showing sideways momentum. The price is currently testing key support at $1.60. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 7.8% recently.
Market Sentiment: ENVB has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $10.00 (+553.6%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, ENVB is showing sideways momentum. The price is currently testing key support at $1.60. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 7.8% recently.
Market Sentiment: ENVB has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $10.00 (+553.6%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$1.79 -
$2.81
Company Quality Score
40/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
52.6%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-7.8%)
- BULLISH: Trading 553.6% below Wall St target ($10.00)
- CAUTION: 5-day price weakness (-15.0%) - monitor closely
Trading Range Analysis
30-Day Trading Range
$1.79 -
$2.81
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$1.60
Resistance Level
$2.41
Current Trend
Sideways
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
23.09
Wall Street Target
$10.00
(+553.6%)
Revenue Growth (YoY)
-7.3%
Share & Embed Analysis
Last updated: June 15, 2026 8:23 AM ET
Data refreshes hourly during market hours. Next update: 9:23 AM
Data refreshes hourly during market hours. Next update: 9:23 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ENVB showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$27 | 50 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$412 | 51 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$275 | 61 BUY |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$109 | 59 HOLD |
|
CRNX
Crinetics Pharmaceutical… |
STRONG BUY
17 analysts |
$83 | 54 HOLD |
